Скачать или смотреть Novo Nordisk vs 1 Million GLP-1 Patients

Novo Nordisk Earnings Call: Implications for GLP-1 Users and the Future of Obesity Treatment

In this episode of The Downsized, host Christopher Durham reviews Novo Nordisk's Q2 2025 earnings call, revealing significant financial growth but a surprising full-year forecast reduction. Despite 18% growth in sales and 29% growth in operating profit, Novo has had to lower its forecast due to slowing GLP-1 growth in the U.S., partly attributed to compounded medications. Key revelations from the call include Novo's legal actions against compounded GLP-1 providers, the need for more affordable pricing to combat competition, and the potential of Novo's innovation pipeline, including new GLP-1 formulations and cardiovascular outcomes. Durham emphasizes the growing power of patient choices in shaping the market, urging Novo to reduce drug prices and expand access. The episode ends with a preview of Eli Lilly's upcoming earnings call, promising more insights into the future of obesity treatment.

SIGN THE PETITION TO ASK KELLY TO JOIN US: https://www.change.org/downsizedkelly

RSVP FOR A FREE MEETUP: https://thedownsized.org/meet-ups/

DOWNSIZED WEBSITE: https://thedownsized.org/

BOOK THE DOWNSIZED AT SEA CRUISE 2026: https://thedownsized.org/downsized-at... JOIN CLUB DOWNSIZED: https://www.youtube.com/@thedownsized...

DOWNSIZED GLP-1 COMPANION PRODUCT STORE: https://thedownsized.org/downsized-store As an Amazon Associate, I earn from qualifying purchases.

FOR SPONSORSHIPS, BRAND DEALS & COLLABS: https://thedownsized.org/contact/

ME AGAIN APP: https://apps.apple.com/us/app/meagain...

Replenza's free lifestyle guide:https://www.replenzalabs.com/pages/li...
33% off Replenza bundle: https://www.replenzalabs.com/products...

00:00 Introduction and Novo Nordisk Earnings Overview
00:29 Impact of Compounded Medications on Novo's Business
01:31 Personal Story and Disclaimer
02:24 Detailed Analysis of Novo's Q2 2025 Earnings Call
04:29 Legal Actions Against Compounded Semaglutide
05:52 Affordability and Access Issues
07:04 Pricing Reset
08:28 CVS Caremark
10:54 Novo's Innovation Pipeline and Future Strategies
15:14 International Sales & Strategic Shift
19:05 Competitive Landscape and Cardiovascular Outcomes
21:26 Conclusion and Call to Action